Posted by Michael Wonder on 26 Mar 2022
Landmark PBS listing for Australians with cystic fibrosis
27 March 2022 - From April 1 2022, Trikafta (elexacaftor with tezacaftor and ivacaftor and ivacaftor) will be available on the PBS for the first time for Australians with cystic fibrosis aged 12 years and older, who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
F508del is the most common mutation.
In Australia, one in 2,500 babies are born with cystic fibrosis and there is currently no cure.
